This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Vifor Pharma Dividend
Dividend criteriumcontroles 3/6
Belangrijke informatie
1.1%
Dividendrendement
88%
Uitbetalingsratio
| Gemiddelde opbrengst industrie | 2.2% |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | n/a |
| Winst per aandeel | US$2.26 |
| Dividendrendementsvoorspelling | 1.1% |
Recente dividendupdates
Recent updates
Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: GNHA.F's dividends per share have been stable in the past 10 years.
Groeiend dividend: GNHA.F's dividend payments have increased over the past 10 years.
Dividendrendement versus markt
| Vifor Pharma Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (GNHA.F) | 1.1% |
| Markt onderkant 25% (US) | 1.4% |
| Markt Top 25% (US) | 4.4% |
| Gemiddelde industrie (Pharmaceuticals) | 2.2% |
| Analist prognose (GNHA.F) (tot 3 jaar) | 1.1% |
Opmerkelijk dividend: GNHA.F's dividend (1.11%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.6%).
Hoog dividend: GNHA.F's dividend (1.11%) is low compared to the top 25% of dividend payers in the US market (4.56%).
Winstuitkering aan aandeelhouders
Verdiendekking: At its current payout ratio (88.5%), GNHA.F's payments are covered by earnings.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: Insufficient data to calculate cash payout ratio to determine if its dividend payments are covered by cash flows.